Wall Street is positive on Biofrontera AG (BFRA). On average, analysts give Biofrontera AG a Strong Buy rating. The average price target is $8, which means analysts expect the stock to rise by 127.27% over the next twelve months. That average ranking earns Biofrontera AG an Analyst Rating of 73, which is better than 73% of stocks based on data compiled by InvestorsObserver.
Biofrontera AG (BFRA) Stock: Do Analysts Think You Should Sell?
Wall Street analysts are rating BFRA a Strong Buy today. Find out what this means to you and get the rest of the rankings on BFRA!